Call us: 0808 171 2455
You may be aware that there has been a National Institute for Health and Care Excellence (NICE) recommendation to not support the NICE TA558 guidance and discontinue Cancer Drugs Fund (CDF) funding of adjuvant nivolumab in high risk resected malignant melanoma.
For two years, this treatment had been authorised use within the CDF as an option for the adjuvant treatment of completely resected melanoma in adults with lymph node involvement or metastatic disease. This treatment allowed patients to access the drug while data was collected to address questions surrounding its clinical benefit. However, NICE says that the data from the CDF and a key clinical trial is too immature. Had this treatment been approved for routine use it is estimated that around 1,480 people would have been eligible to receive this treatment.
Melanoma UK represents thousands of patients throughout the UK and is acutely aware of the impact that a negative decision will have on the lives of patients, families and clinicians. The melanoma patient community is devastated by this decision and is urging NICE to reconsider and overturn.
We are writing to NICE to express our objection to the recommendation to not support the NICE TA558 guidance and hence discontinue CDF funding of adjuvant nivolumab in high risk resected malignant melanoma.
You now have an opportunity to have your voice heard by submitting your comments below.